SCHEMBL4205152

SCHEMBL4205152

CCN(CC)CCS(=O)(=O)N1CC[CH]CC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
PIK3CD O00329 1/20 0.33
PIK3R1 P27986 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RYR2 Q92736 1/20 0.33
KDM4E B2RXH2 3/20 0.32
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32
GLA P06280 1/20 0.32
POLB P06746 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
IKBKB O14920 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4197849 0.90 LMNA (0.43) LMNAL3MBTL1RYR2KDM4EGAA
SCHEMBL4507280 0.81 IKBKB (0.33) LMNAPIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL4288139 0.79 L3MBTL1 (0.49) LMNAL3MBTL1KDM4EGAAPKM
SCHEMBL4202856 0.78 CYP2D6 (0.32) LMNAL3MBTL1KDM4EGAAPKM
SCHEMBL1377831 0.78 HSD17B10 (0.40) LMNAL3MBTL1KDM4EPKMPOLB
SCHEMBL4204826 0.77 POLB (0.30) L3MBTL1POLB
SCHEMBL4191321 0.77 LMNA (0.34) LMNAGAAHSD17B10IKBKB
SCHEMBL2430904 0.76 LMNA (0.46) LMNAL3MBTL1KDM4EGAAPOLB
SCHEMBL4199003 0.75 BRD4 (0.36) LMNAPIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL4195825 0.75 SIGMAR1 (0.42) LMNAPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2009-11-05 US disclosed
CN-101500569-A HIF hydroxylase inhibitors for treatment of anemia of cancer FIBROGEN INC (US) 2009-08-05 CN disclosed
CN-101490041-A 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation ASTRAZENECA AB (SE) 2009-07-22 CN disclosed
EP-2032559-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2009-03-11 EP disclosed
WO-2007138268-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION CCNI, MKI67, CDK2 LMNA 2945/4885PIK3CD 533/4885PIK3R1 1738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.